# Fir Creek Capital

> Fir Creek Capital is a VC fund backing Health Care, Medical and Biotechnology. See 11 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 11
- Last investment: Jul 2026
- Lead investor: 64%
- Last updated: Aug 2026

Fir Creek Capital is a cutting-edge investment fund in the field of biomedicine and health.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 36% |
| Medical | 3 | 27% |
| Biotechnology | 3 | 27% |
| Retail | 1 | 9% |
| Genetics | 1 | 9% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Angel | 4 | 36% |
| Seed | 2 | 18% |
| Series A | 2 | 18% |
| Series B | 2 | 18% |
| Series C | 1 | 9% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Pinsun Bio | Pinsun Bio is a technology innovation-driven company that focuses on core consumables and one-stop solutions for biopharmaceutical processes. | $14.8M | Series A | Jul 20, 2026 |  |
| Aowo Biotech | Aowo Biotech focuses on the field of regenerative medicine, with core investments in stem cell technology. |  | Angel | Feb 26, 2026 |  |
| Regend Therapeutics | Regend Therapeutics focuses on the human organ regenerative medicine business and is a global leader in this field. Its core product REGEND001 cell preparation has been accepted by the State Food and Drug Administration and is the world's first autologous stem cell product for respiratory diseases. The company is also the first company inChina to be registered by the National Health and Health Commission and the Food and Drug Administration, and is allowed to conduct clinical research on stem cells (Registration No.: CMR-20161214-1002). It is also the first batch of key research and development programs of the Ministry of Science and Technology. And companies that transform research topics. At present, the company has passed ISO9001:2008 quality management system certification, and the stem cell preparation has passed the China Metrology Accreditation (CMA), China Conformity Assessment Committee (CNAS) and IAF International Mutual Recognition. All clinical programs of Jimmy Suisheng are strictly in accordance with the regulations of the National Health Care Commission and the Food and Drug Administration, and are registered with the National Trial Global Database of the National Institutes of Health. | $50.6M | Series C | Feb 11, 2026 |  |
| Shentuo Biotechnology | Shentuo Biotechnology is a platform for gene therapy and revolutionary delivery technology that focuses on novel gene therapy medication developments. | $1.4M | Angel | Sep 28, 2025 |  |
| Regend Therapeutics | Regend Therapeutics focuses on the human organ regenerative medicine business and is a global leader in this field. Its core product REGEND001 cell preparation has been accepted by the State Food and Drug Administration and is the world's first autologous stem cell product for respiratory diseases. The company is also the first company inChina to be registered by the National Health and Health Commission and the Food and Drug Administration, and is allowed to conduct clinical research on stem cells (Registration No.: CMR-20161214-1002). It is also the first batch of key research and development programs of the Ministry of Science and Technology. And companies that transform research topics. At present, the company has passed ISO9001:2008 quality management system certification, and the stem cell preparation has passed the China Metrology Accreditation (CMA), China Conformity Assessment Committee (CNAS) and IAF International Mutual Recognition. All clinical programs of Jimmy Suisheng are strictly in accordance with the regulations of the National Health Care Commission and the Food and Drug Administration, and are registered with the National Trial Global Database of the National Institutes of Health. |  | Series B | Feb 10, 2025 |  |
| Cadvis Biotechnology | Cadvis Biotechnology focuses on diagnostic reagents, revolutionary biological therapeutics, and technology research and services, including early prevention, early screening, early diagnosis, intraoperative auxiliary diagnosis, and treatment of tumor disorders, particularly gynecological cancers. | $27.5M | Series B | Dec 05, 2024 |  |
| Kunlun Precision | Kunlun Precision is a laser precision manufacturing service provider that focuses on the design integration and control system development of laser extreme advanced manufacturing equipment and devices, as well as supplying cross-scale laser manufacturing systems. |  | Angel | Nov 28, 2024 |  |
| Kunlun Precision | Kunlun Precision is a laser precision manufacturing service provider that focuses on the design integration and control system development of laser extreme advanced manufacturing equipment and devices, as well as supplying cross-scale laser manufacturing systems. |  | Seed | Nov 28, 2024 |  |
| Saihe Biotech | Saihe Biotech is a developer of radioactive cancer therapy pharmaceuticals dedicated to being a global leader in nuclear medicine innovation by creating original core technologies with complete intellectual property rights. |  | Seed | Nov 21, 2024 |  |
| Saihe Biotech | Saihe Biotech is a developer of radioactive cancer therapy pharmaceuticals dedicated to being a global leader in nuclear medicine innovation by creating original core technologies with complete intellectual property rights. |  | Angel | Nov 21, 2024 |  |

10 of 11 investments shown.

## Co-investors
- [SND Ventures Group](https://shizune.co/investors/profile/snd-ventures-group) — VC Fund, 2 deals together
- [Yongxin Capital](https://shizune.co/investors/profile/yongxin-capital) — VC Fund, 2 deals together
- [Angel Plus China](https://shizune.co/investors/profile/angel-plus-china) — VC Fund, 1 deal together
- [Chuchuang Investment](https://shizune.co/investors/profile/chuchuang-investment) — VC Fund, 1 deal together
- [EFung Capital](https://shizune.co/investors/profile/efung-capital) — VC Fund, 1 deal together
- Gongqingcheng Fuhui — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [LVX Ventures](https://shizune.co/investors/profile/letsventure) — VC Fund
- [ZhenFund](https://shizune.co/investors/profile/zhenfund) — VC Fund
- [IAN Group](https://shizune.co/investors/profile/indian-angel-network) — VC Fund

## FAQ

### What does Fir Creek Capital invest in?

Fir Creek Capital invests primarily in Health Care, Medical and Biotechnology startups, most often at Angel and Seed stage. Most of the 11 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Fir Creek Capital last invest?

The most recent investment recorded for Fir Creek Capital closed in Jul 2026. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co